AMBER NELSON: Open Payments
NPI 1841650561 · HOOVER, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,965 in 116 payments from 23 companies in 2025. Trend: 2023 $819 · 2024 $1,747 · 2025 $2,965
Food & beverage: $2,820Education: $145
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 20 | $477 |
| Regeneron Healthcare Solutions, Inc. | 14 | $441 |
| AstraZeneca Pharmaceuticals LP | 13 | $410 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $246 |
| Amgen Inc. | 11 | $184 |
| GENZYME CORPORATION | 6 | $169 |
| Organon LLC | 5 | $166 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $161 |
| Novartis Pharmaceuticals Corporation | 6 | $143 |
| Genentech USA, Inc. | 6 | $130 |
Products named: DUPIXENT, TEZSPIRE, NUCALA, NEFFY, Xolair, TRELEGY ELLIPTA, AIRSUPRA, VTAMA.
Industry payments across AL — which companies pay providers there.
